Pravastatin and Placental Insufficiency Associated Disorders: A Systematic Review and Meta-analysis

Overview

Journal Front Pharmacol

Date 2022 Nov 28

PMID 36438820

Authors

Ayala Hirsch

Reut Rotem

Natali Ternovsky

Bruria Hirsh Raccah

Affiliations

Soon will be listed here.

Abstract

Uteroplacental insufficiency associated disorders, such as preeclampsia, fetal growth restriction and obstetrical antiphospholipid syndrome, share pathophysiology and risk factors with cardiovascular diseases treated with statins. To evaluate pregnancy outcomes among women with uteroplacental insufficiency disorders who were treated with statins. Electronic databases were searched from inception to January 2022 Cohort studies and randomized controlled trials. Pooled odds ratios were calculated using a random-effects model; meta-regression was utilized when applicable. The analysis included ten studies describing 1,391 women with uteroplacental insufficiency disorders: 703 treated with pravastatin and 688 not treated with statins. Women treated with pravastatin demonstrated significant prolongation of pregnancy (mean difference 0.44 weeks, 95%CI:0.01-0.87, = 0.04, I = 96%) and less neonatal intensive care unit admissions (OR = 0.42, 95%CI: 0.23-0.75, = 0.004, I = 25%). In subgroup analysis, prolongation of pregnancy from study entry to delivery was statistically significant in cohort studies (mean difference 8.93 weeks, 95%CI:4.22-13.95, = 0.00) but not in randomized control studies. Trends were observed toward a decrease in preeclampsia diagnoses (OR = 0.54, 95%CI:0.27-1.09, = 0.09, I = 44%), perinatal death (OR = 0.32, 95%CI:0.09-1.13, = 0.08, I = 54%) and an increase in birth weight (mean difference = 102 g, 95%CI: -14-212, = 0.08, I = 96%). A meta-regression analysis demonstrated an association between earlier gestational age at initiation of treatment and a lower risk of preeclampsia development (R = 1). Pravastatin treatment prolonged pregnancy duration and improved associated obstetrical outcomes in pregnancies complicated with uteroplacental insufficiency disorders in cohort studies. https://www.crd.york.ac.uk/prospero/ identifier CRD42020165804 17/2/2020.

References

Saito S, Takagi K, Moriya J, Kobayashi T, Kanayama N, Sameshima H . A randomized phase 3 trial evaluating antithrombin gamma treatment in Japanese patients with early-onset severe preeclampsia (KOUNO-TORI study): Study protocol. Contemp Clin Trials. 2021; 107:106490. DOI: 10.1016/j.cct.2021.106490. View

Cudmore M, Ahmad S, Al-Ani B, Fujisawa T, Coxall H, Chudasama K . Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. Circulation. 2007; 115(13):1789-97. DOI: 10.1161/CIRCULATIONAHA.106.660134. View

Ruys T, Maggioni A, Johnson M, Sliwa K, Tavazzi L, Schwerzmann M . Cardiac medication during pregnancy, data from the ROPAC. Int J Cardiol. 2014; 177(1):124-8. DOI: 10.1016/j.ijcard.2014.09.013. View

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

Laufs U, Fata V, Liao J . Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem. 1998; 272(50):31725-9. DOI: 10.1074/jbc.272.50.31725. View

Caroli-Bosc F, Le Gall P, Pugliese P, Delabre B, Demarquay J, DELMONT J . Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population. Dig Dis Sci. 2001; 46(3):540-4. DOI: 10.1023/a:1005643014395. View

Winterfeld U, Allignol A, Panchaud A, Rothuizen L, Merlob P, Cuppers-Maarschalkerweerd B . Pregnancy outcome following maternal exposure to statins: a multicentre prospective study. BJOG. 2012; 120(4):463-71. DOI: 10.1111/1471-0528.12066. View

Edison R, Muenke M . Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins. Am J Med Genet A. 2004; 131(3):287-98. DOI: 10.1002/ajmg.a.30386. View

Desai R, Rothman K, Bateman B, Hernandez-Diaz S, Huybrechts K . A Propensity-score-based Fine Stratification Approach for Confounding Adjustment When Exposure Is Infrequent. Epidemiology. 2016; 28(2):249-257. PMC: 5497217. DOI: 10.1097/EDE.0000000000000595. View

10.

Zeisler H, Llurba E, Chantraine F, Vatish M, Staff A, Sennstrom M . Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. N Engl J Med. 2016; 374(1):13-22. DOI: 10.1056/NEJMoa1414838. View

11.

Colvin L, Slack-Smith L, Stanley F, Bower C . Linking a pharmaceutical claims database with a birth defects registry to investigate birth defect rates of suspected teratogens. Pharmacoepidemiol Drug Saf. 2010; 19(11):1137-50. DOI: 10.1002/pds.1995. View

12.

Costantine M, Cleary K, Hebert M, Ahmed M, Brown L, Ren Z . Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial. Am J Obstet Gynecol. 2016; 214(6):720.e1-720.e17. PMC: 4884459. DOI: 10.1016/j.ajog.2015.12.038. View

13.

Brownfoot F, Tong S, Hannan N, Binder N, Walker S, Cannon P . Effects of Pravastatin on Human Placenta, Endothelium, and Women With Severe Preeclampsia. Hypertension. 2015; 66(3):687-97. DOI: 10.1161/HYPERTENSIONAHA.115.05445. View

14.

Ray K, Cannon C . The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol. 2005; 46(8):1425-33. DOI: 10.1016/j.jacc.2005.05.086. View

15.

Chaddha V, Viero S, Huppertz B, Kingdom J . Developmental biology of the placenta and the origins of placental insufficiency. Semin Fetal Neonatal Med. 2005; 9(5):357-69. DOI: 10.1016/j.siny.2004.03.006. View

16.

Vahedian-Azimi A, Makvandi S, Banach M, Reiner Z, Sahebkar A . Fetal toxicity associated with statins: A systematic review and meta-analysis. Atherosclerosis. 2021; 327:59-67. DOI: 10.1016/j.atherosclerosis.2021.05.006. View

17.

Davignon J . Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004; 109(23 Suppl 1):III39-43. DOI: 10.1161/01.CIR.0000131517.20177.5a. View

18.

Roberts J, Cooper D . Pathogenesis and genetics of pre-eclampsia. Lancet. 2001; 357(9249):53-6. DOI: 10.1016/s0140-6736(00)03577-7. View

19.

Costantine M, West H, Wisner K, Caritis S, Clark S, Venkataramanan R . A randomized pilot clinical trial of pravastatin versus placebo in pregnant patients at high risk of preeclampsia. Am J Obstet Gynecol. 2021; 225(6):666.e1-666.e15. PMC: 8611118. DOI: 10.1016/j.ajog.2021.05.018. View

20.

Saad A, Kechichian T, Yin H, Sbrana E, Longo M, Wen M . Effects of pravastatin on angiogenic and placental hypoxic imbalance in a mouse model of preeclampsia. Reprod Sci. 2013; 21(1):138-45. DOI: 10.1177/1933719113492207. View